Company press releases
| Released | Company | Title | Industry | Topic |
|---|---|---|---|---|
| 27 Jun 2023 14:26 CEST |
NORDIC NANOVECTOR | NANOV AGM - Disclosure of proxies | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 27 Jun 2023 14:10 CEST |
NORDIC NANOVECTOR | NANOV AGM - Publication of Exempted Document | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 23 Jun 2023 16:27 CEST |
NORDIC NANOVECTOR | NANOV - Endring i forslag til vedtak 14 på GF 28.juni 2023 | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 22 Jun 2023 14:36 CEST |
NORDIC NANOVECTOR | Jostein Dahle, Chief Scientific Officer and Co-Founder, leaves the Company | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 22 Jun 2023 14:36 CEST |
NORDIC NANOVECTOR | Jostein Dahle forlater Nordic Nanovector | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 15 Jun 2023 13:13 CEST |
NORDIC NANOVECTOR | Nordic Nanovector - GF vedlegg | 20103010 Biotechnology | Årsrapporter og revisjonsberetninger |
| 15 Jun 2023 13:13 CEST |
NORDIC NANOVECTOR | Nordic Nanovector - AGM attachments | 20103010 Biotechnology | Annual financial and audit Reports |
| 07 Jun 2023 14:46 CEST |
NORDIC NANOVECTOR | Nordic Nanovector - Mandatory notification of trade - primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 07 Jun 2023 14:30 CEST |
NORDIC NANOVECTOR | Nordic Nanovector - Notice of Annual General Meeting on 28 June 2023 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 07 Jun 2023 13:44 CEST |
NORDIC NANOVECTOR | The Chairman of the Board buys shares in Nordic Nanovector | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 07 Jun 2023 13:44 CEST |
NORDIC NANOVECTOR | Styreleder kjøper aksjer i Nordic Nanovector | 20103010 Biotechnology | Meldepliktig handel for primærinnsidere |
| 06 Jun 2023 20:37 CEST |
NORDIC NANOVECTOR | NANOV announces agreement to acquire Thor Medical | 20103010 Biotechnology | Innsideinformasjon |
| 06 Jun 2023 20:10 CEST |
NORDIC NANOVECTOR | Nordic Nanovector announces agreement to acquire Thor Medical, an emerging producer of alpha-emitters for radiopharmaceuticals to treat cancer | 20103010 Biotechnology | Inside information |
| 18 Apr 2023 11:15 CEST |
NORDIC NANOVECTOR | Nordic Nanovector Publishes Data from the PARADIGME Phase 2 Clinical Trials with Betalutin® on European Clinical Trials Database | 20103010 Biotechnology | Non-regulatory press releases |
| 31 Mar 2023 08:45 CEST |
NORDIC NANOVECTOR | NORDIC NANOVECTOR - ANNUAL GENERAL MEETING POSTPONED | 20103010 Biotechnology | Non-regulatory press releases |
| 23 Mar 2023 11:00 CET |
NORDIC NANOVECTOR | NORDIC NANOVECTOR - ANNUAL AND REMUNERATION REPORTS APPROVED | 20103010 Biotechnology | Annual financial and audit Reports |
| 28 Feb 2023 07:00 CET |
NORDIC NANOVECTOR | Nordic Nanovector ASA Results for the Second Half and Full Year 2022 | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
| 21 Feb 2023 11:00 CET |
NORDIC NANOVECTOR | Nordic Nanovector ASA: Invitation to Second Half and Full Year 2022 Results Presentation and Webcast | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 31 Jan 2023 23:15 CET |
NORDIC NANOVECTOR | Nordic Nanovector ASA announces that Ludvik Sandnes has been appointed interim Chief Executive Officer (CEO) and Chief Financial Officer (CFO) | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 19 Jan 2023 20:10 CET |
NORDIC NANOVECTOR | Nordic Nanovector board member resigns | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 16 Jan 2023 22:54 CET |
NORDIC NANOVECTOR | Nordic Nanovector ASA Notes Publication of Letter by Largest Shareholder North Energy | 20103010 Biotechnology | Non-regulatory press releases |
| 03 Jan 2023 17:59 CET |
NORDIC NANOVECTOR | Nordic Nanovector ASA: Extraordinary General Meeting held | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 03 Jan 2023 10:57 CET |
NORDIC NANOVECTOR | Flagging Nordic Nanovector ASA | 20103010 Biotechnology | Flagging |
| 02 Jan 2023 17:44 CET |
NORDIC NANOVECTOR | NOTIFICATION OF MAJOR HOLDINGS | 20103010 Biotechnology | Major shareholding notifications |
| 16 Dec 2022 10:37 CET |
NORDIC NANOVECTOR | Flaggemelding | 20103010 Biotechnology | Major shareholding notifications |
| 16 Dec 2022 10:20 CET |
NORDIC NANOVECTOR | Flagging i Nordic Nanovector ASA | 20103010 Biotechnology | Flagging |
| 13 Dec 2022 11:48 CET |
NORDIC NANOVECTOR | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 13 Dec 2022 10:47 CET |
NORDIC NANOVECTOR | Nordic Nanovector ASA - Notice of Extraordinary General Meeting on 3 January 2023 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 09 Dec 2022 18:32 CET |
NORDIC NANOVECTOR | Nordic Nanovector update following shareholder vote against proposed merger with APIM Therapeutics | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 05 Dec 2022 15:48 CET |
NORDIC NANOVECTOR | Flagging Nordic Nanovector ASA 05.12.2022 | 20103010 Biotechnology | Flagging |
| 01 Dec 2022 12:23 CET |
NORDIC NANOVECTOR | Nordic Nanovector ASA: Extraordinary General Meeting held | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 25 Nov 2022 12:50 CET |
NORDIC NANOVECTOR | Nordic Nanovector Launches Dedicated Area on its Website in Norwegian for Information on the Proposed Merger with APIM Therapeutics | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 23 Nov 2022 07:00 CET |
NORDIC NANOVECTOR | Nordic Nanovector: Invitation to webcast regarding proposed merger with APIM Therapeutics | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 21 Nov 2022 08:01 CET |
NORDIC NANOVECTOR | Nordic Nanovector comment on Proposed Merger with APIM Therapeutics | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 17 Nov 2022 16:07 CET |
NORDIC NANOVECTOR | Flagging Nordic Nanovector ASA 17.11.2022 | 20103010 Biotechnology | Flagging |
| 10 Nov 2022 18:04 CET |
NORDIC NANOVECTOR | Nordic Nanovector ASA - Notice of Extraordinary General Meeting on 1 December 2022 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 09 Nov 2022 21:38 CET |
NORDIC NANOVECTOR | Nordic Nanovector and APIM Therapeutics Announce Merger Agreement | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 03 Nov 2022 14:01 CET |
NORDIC NANOVECTOR | Nordic Nanovector Highlights Novel Humanized Anti-CD37 Therapeutic Antibody Candidates for B-cell Malignancies or B-cell-driven Autoimmune Disorders at ASH Annual Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 15 Sep 2022 18:15 CEST |
NORDIC NANOVECTOR | Nordic Nanovector consolidates Board to conserve resources while it explores strategic options | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 31 Aug 2022 07:00 CEST |
NORDIC NANOVECTOR | Nordic Nanovector ASA Results for the Second Quarter and First Half 2022 | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
| 26 Aug 2022 16:43 CEST |
NORDIC NANOVECTOR | Nordic Nanovector consolidates senior leadership team and restructures to conserve resources as it explores strategic options | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 24 Aug 2022 15:31 CEST |
NORDIC NANOVECTOR | Nordic Nanovector ASA: Invitation to Second Quarter and First Half 2022 Results Presentation Webcast | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 18 Aug 2022 19:16 CEST |
NORDIC NANOVECTOR | Nordic Nanovector to explore strategic options | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 15 Jul 2022 14:25 CEST |
NORDIC NANOVECTOR | Nordic Nanovector ASA - flagging | 20103010 Biotechnology | Flagging |
| 13 Jul 2022 08:04 CEST |
NORDIC NANOVECTOR | Mandatory disclosure notification | 20103010 Biotechnology | Major shareholding notifications |
| 06 Jul 2022 08:32 CEST |
NORDIC NANOVECTOR | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 05 Jul 2022 21:26 CEST |
NORDIC NANOVECTOR | Nordic Nanovector to Discontinue PARADIGME, its Phase 2b Trial with Betalutin[®] in 3L R and R Follicular Lymphoma | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 21 Jun 2022 16:31 CEST |
NORDIC NANOVECTOR | Nordic Nanovector to Seek Regulatory Feedback Following its Preliminary Review and Independent Data Evaluation of PARADIGME, its Phase 2b Trial with Betalutin® in R/R Follicular Lymphoma | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 10 Jun 2022 10:13 CEST |
NORDIC NANOVECTOR | Nordic Nanovector Announces that the data from the LYMRIT 37-05 Phase 1 Trial of Betalutin® in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) will be presented at EHA 2022 Meeting | 20103010 Biotechnology | Non-regulatory press releases |
| 02 Jun 2022 07:00 CEST |
NORDIC NANOVECTOR | Nordic Nanovector to Conduct a Comprehensive Review and Independent Data Evaluation of PARADIGME, its Phase 2b Trial with Betalutin® in R/R FL as a Result of Continuing Slow Recruitment | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |